Explained: Can you mix and match two-dose coronavirus vaccines?

So far, limited data suggests an AstraZeneca shot followed by the Pfizer shot is safe and effective.

Vials, Vaccine
Photo: Shutterstock
AP London
2 min read Last Updated : Jun 17 2021 | 1:56 PM IST

Can you mix and match two-dose COVID-19 vaccines? It's likely safe and effective, but researchers are still gathering data to be sure.

The authorised COVID-19 shots around the world are all designed to stimulate your immune system to produce virus-fighting antibodies, though the way they do so varies, noted Dr. Kate O'Brien, director of the World Health Organization's vaccine unit.

Based on the basic principles of how vaccines work, we do think that the mix-and-match regimens are going to work, she said.

Scientists at Oxford University in the United Kingdom are testing combinations of the two-dose COVID-19 vaccines made by AstraZeneca, Moderna, Novavax and Pfizer-BioNTech. Smaller trials are also ongoing in Spain and Germany.

We really just need to get the evidence in each of these (vaccine) combinations, O'Brien said.

So far, limited data suggests an AstraZeneca shot followed by the Pfizer shot is safe and effective. The combination also appears to come with a slightly higher likelihood of temporary side effects like aches and chills.

That might be because mixing and matching different types of vaccines can often produce a stronger immune response, said Lawrence Young, a virologist at the University of Warwick in the United Kingdom.

In some places, health officials already suggest mixing in select circumstances.

After the AstraZeneca vaccine was linked to extremely rare blood clots, many European countries including Germany, France and Spain recommended people who got it as a first dose get a Pfizer or Moderna shot as a second dose instead.

In Britain and Canada, officials say people should aim to get the same vaccine for their second dose if possible. If they got AstraZeneca as their first shot, they're advised to get another vaccine only if they have a history of blood clots or other conditions that might put them at higher risk of clots.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Jun 17 2021 | 1:55 PM IST

Next Story